CHICAGO, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data and University of California Davis Comprehensive Cancer Center are collaborating on a precision medicine partnership to advance clinical care with Next Generation Sequencing analysis, focused initially on patients diagnosed with hematological malignancies and pancreatic cancer.
As part of the collaboration, Tempus will do molecular sequencing and analysis for a group of patients at UC Davis Comprehensive Cancer Center. Utilizing machine learning and advanced bioinformatics, Tempus helps physicians analyze data sets in a search for potentially relevant patterns that can help guide treatment for patients who are unlikely to respond to conventional therapies or for whom no conventional therapies exist.
Technology has come a long way since researchers first mapped the genome more than 15 years ago and yet physicians and their patients have not widely benefited, said Eric Lefkofsky, Founder and CEO at Tempus. We are excited to bring the Tempus platform to physicians at the UC Davis Comprehensive Cancer Center who will now have access to technology and analytics that will support their efforts to deliver personalized treatment for each patient.
Tempus will work with a team of investigators led by Dr. Primo Lara, an esteemed investigator in clinical-translational research, who has chaired a number of cancer clinical trials from phase I to III.
Discovery is happening at a rapid pace and will continue to accelerate with access to data-driven tools designed to support work in the clinic, said Dr. Lara, Interim Director of the UC Davis Comprehensive Cancer Center. Working with Tempus is consistent with our commitment to providing our physicians with the tools and resources they need to best treat their patients.
The UC Davis Comprehensive Cancer Center is among the top-ranked national cancer programs for both research and patient care. It is one of 48 centers designated "comprehensive" by the National Cancer Institute.
About Tempus: Tempus is a technology company that is building the worlds largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs).
About UC Davis Comprehensive Cancer CenterUC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 10,000 adults and children every year, and access to more than 125 clinical trials at any given time. Its innovative research program engages more than 280 scientists at UC Davis, Lawrence Livermore National Laboratory and Jackson Laboratory (JAX West), whose scientific partnerships advance discovery of new tools to diagnose and treat cancer. Through the Cancer Care Network, UC Davis collaborates with hospitals and clinical centers throughout the Central Valley and Northern California to offer the latest cancer-care services to their communities. UC Davis community-based outreach and education programs address disparities in cancer outcomes across diverse populations. For more information, visit http://cancer.ucdavis.edu.
Read more here:
Tempus and University of California Davis Comprehensive Cancer ... - GlobeNewswire (press release)
- Dr Diaz on the Evolution of Precision Medicine in Cervical Cancer - OncLive - May 5th, 2024
- Advancing genomic medicine: The evolution of personalized cancer treatment in Japan - Medical Xpress - May 5th, 2024
- Rymedi and Precision Genetics Announce Strategic Partnership to Advance Precision Medicine and Healt - PharmiWeb.com - May 5th, 2024
- Autologous Cell Therapy Market: Advancements in Personalized Medicine and Regenerative Treatments | 2023-2029 - WhaTech - May 5th, 2024
- Precision Medicine Revolution: Rymedi and Precision Genetics Join Forces - CoinTrust - May 5th, 2024
- Tiny tool: Microneedles that can bend and stretch to redefine healthcare - Interesting Engineering - May 5th, 2024
- Oncology Precision Medicine Market Research, Industry Trends and Global Forecasts, 2035 - Rising Partnership and ... - PR Newswire - March 18th, 2024
- 3 Precision Medicine Stocks That Could Benefit From the Industry's Rise - InvestorPlace - March 18th, 2024
- Prime Editing Approach Provides a Faster, More Effective Way to Screen for Cancer Mutations - Inside Precision Medicine - March 18th, 2024
- Global Genomics Industry Research 2024-2031: Rising Adoption of Personalized Medicines and Gene Therapies ... - PR Newswire - March 18th, 2024
- CAR T-Cell Therapy Successfully Used to Treat Brain Tumors - Inside Precision Medicine - March 18th, 2024
- Revolutionizing Wellness: The Power of Personalised Health Tech - AutoGPT - March 18th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- AI and predictive medicine: Recent advances - News-Medical.Net - March 10th, 2024
- Personalized medicine is coming, but who will have access to it? - AAMC - March 10th, 2024
- Why personalized medicine is a business trend to watch in 2024 - HealthLeaders Media - March 10th, 2024
- AI helps cardiologists deliver personalized healthcarebut there is still plenty of work to do - Cardiovascular Business - March 10th, 2024
- Q&A: How AI and wearable technologies are transforming medicine - EMS1.com - March 10th, 2024
- HealthTech Revolution: Wearables, AI, and the Personalized Future of Healthcare - GearBrain - March 10th, 2024
- Redefining Healthcare: The Rise of Personalized Medicine and the Shift from Conventional Care - Medriva - March 10th, 2024
- Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer - OncLive - March 10th, 2024
- Chemotherapy Plus High Doses of Radiation Effective for Treating Non-Small Cell Lung Cancer - Inside Precision Medicine - January 17th, 2024
- It's Time to Fully Embrace Precision Medicine's Promise in Pediatrics - Healthcare Innovation - January 17th, 2024
- Special Report: Radiation Oncology Takeaways from RSNA23 - Imaging Technology News - January 17th, 2024
- Advanced Therapeutics Pharmaceutical Outsourcing Market to Surge at a CAGR of 4.4% by 2034 Amid Growing ... - PR Newswire - January 17th, 2024
- Simulations of the human body and advanced data promise more personalized medical treatment - Medical Xpress - January 17th, 2024
- United States Single Cell Genomics and Proteomics Growth Opportunities: The Integration of Multi-Omics Data to Drive ... - PR Newswire - January 17th, 2024
- Advances Usher In Era of Personalized Treatment for Obesity - Gastroenterology & Endoscopy News - January 17th, 2024
- Unveiling the Reality of Personalized Medicine: Yale Study Highlights Limitations in Current Predictive Models - Medriva - January 17th, 2024
- Digital Twins: The Future of Personalized Healthcare - BNN Breaking - January 17th, 2024
- Healthcare in 2024: A Vision of the Future | Future of Healthcare Predictions - Medriva - January 17th, 2024
- Utilization of the microbiome in personalized medicine - Nature.com - December 22nd, 2023
- Focusing on Women's Health - Inside Precision Medicine - December 22nd, 2023
- Revolutionizing Healthcare: Innovations in Regenerative Medicine Offer Hope - Inside Precision Medicine - December 22nd, 2023
- AI in Genomics Market Predicted to Grow at CAGR of 40.6% by 2031, with Revenue $9.8 Billion - PharmiWeb.com - December 22nd, 2023
- Innovative Technologies Transforming Cancer Treatment - BNN Breaking - December 22nd, 2023
- Antisense Oligonucleotides Industry Poised to Reach US$ 5519.6 Million by 2033-FMI Projection - PharmiWeb.com - December 22nd, 2023
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022